In-host adaptation and acquired triazole resistance in Aspergillus fumigatus: a dilemma for clinical management

The Lancet Infectious Diseases

Volumn 16, Issue 11, 2016, Pages e251-e260

  Verweij, Paul E ^a   Zhang, Jianhua ^b   Debets, Alfons J M ^b   Meis, Jacques F ^a,c   van de Veerdonk, Frank L ^a   Schoustra, Sijmen E ^b   Zwaan, Bas J ^b   Melchers, Willem J G ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b WAGENINGEN UNIVERSITY   (Netherlands)

^c CANISIUS WILHELMINA HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

POLYPEPTIDE ANTIBIOTIC AGENT; TRIAZOLE; ANTIFUNGAL AGENT; TRIAZOLE DERIVATIVE;

ADAPTATION; ANTIFUNGAL RESISTANCE; ASEXUAL REPRODUCTION; ASPERGILLUS FUMIGATUS; ENVIRONMENTAL FACTOR; FUNGAL STRAIN; GENE MUTATION; HUMAN; LUNG ASPERGILLOSIS; NONHUMAN; PARASEXUAL REPRODUCTION; PRIORITY JOURNAL; REPRODUCTION; REVIEW; ASPERGILLOSIS; DRUG EFFECTS; GENETICS; GENOTYPE; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MUTATION; PHYSIOLOGY;

ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; DRUG RESISTANCE, FUNGAL; GENOTYPE; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION; TRIAZOLES;

EID: 84994805898     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(16)30138-4     Document Type: Review

References (74)

1. 1 Latgé, JP, Aspergillus fumigatus and aspergillosis. Clin Microbiol Rev 12 (1999), 310–350.
2. 2 Wiedner, SD, Burnum, KE, Pederson, LM, et al. Multiplexed activity-based protein profiling of the human pathogen Aspergillus fumigatus reveals large functional changes upon exposure to human serum. J Biol Chem 287 (2012), 33447–33459.
3. 3 Mullins, J, Harvey, R, Seaton, A, Sources and incidence of airborne Aspergillus fumigatus (Fres). Clin Allergy 6 (1976), 209–217.
4. 4 Millner, PD, Marsh, PB, Snowden, RB, Parr, JF, Occurrence of Aspergillus fumigatus during composting of sewage sludge. Appl Environ Microbiol 34 (1977), 765–772.
5. 5 Clark, CS, Rylander, R, Larsson, L, Levels of gram-negative bacteria, Aspergillus fumigatus, dust, and endotoxin at compost plants. Appl Environ Microbiol 45 (1983), 1501–1505.
6. 6 Kwon-Chung, KJ, Sugui, JA, Sexual reproduction in Aspergillus species of medical or economical importance: Why so fastidious?. Trends Microbiol 17 (2009), 481–487.
7. 7 Jensen, H, The fungus flora of the soil. Soil Science, 31, 1931, 123.
8. 8 Millner, PD, Bassett, DA, Marsh, PB, Dispersal of Aspergillus fumigatus from sewage sludge compost piles subjected to mechanical agitation in open air. Appl Environ Microbiol 39 (1980), 1000–1009.
9. 9 Kwon-Chung, KJ, Sugui, JA, Aspergillus fumigatus—what makes the species a ubiquitous human fungal pathogen?. PLoS Pathog, 9, 2013, e1003743.
10. 10 Rhodes, JC, Aspergillus fumigatus: growth and virulence. Med Mycol 44 (2006), S77–S81.
11. 11 Kosmidis, C, Denning, DW, The clinical spectrum of pulmonary aspergillosis. Thorax 70 (2015), 270–277.
12. 12 Schoustra, SE, Slakhorst, M, Debets, AJ, Hoekstra, RF, Comparing artificial and natural selection in rate of adaptation to genetic stress in Aspergillus nidulans. J Evol Biol 18 (2005), 771–778.
13. 13 Sniegowski, PD, Gerrish, PJ, Beneficial mutations and the dynamics of adaptation in asexual populations. Philos Trans R Soc Lond B Biol Sci 365 (2010), 1255–1263.
14. 14 Yona, AH, Frumkin, I, Pilpel, Y, A relay race on the evolutionary adaptation spectrum. Cell 163 (2015), 549–559.
15. 15 McDonald, MJ, Rice, DP, Desai, MM, Sex speeds adaptation by altering the dynamics of molecular evolution. Nature 531 (2016), 233–236.
16. 16 Walsh, TJ, Anaissie, EJ, Denning, DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 46 (2008), 327–360.
17. 17 Camps, SM, van der Linden, JW, Li, Y, et al. Rapid induction of multiple resistance mechanisms in Aspergillus fumigatus during azole therapy: a case study and review of the literature. Antimicrob Agents Chemother 56 (2012), 10–16.
18. 18 Howard, SJ, Cerar, D, Anderson, MJ, et al. Frequency and evolution of azole resistance in Aspergillus fumigatus associated with treatment failure. Emerg Infect Dis 15 (2009), 1068–1076.
19. 19 Snelders, E, van der Lee, HA, Kuijpers, J, et al. Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. PLoS Med, 5, 2008, e219.
20. 20 Verweij, PE, Snelders, E, Kema, GHJ, Mellado, E, Melchers, WJG, Azole resistance in Aspergillus fumigatus: a side-effect of environmental fungicide use?. Lancet Infect Dis 9 (2009), 789–795.
21. 21 Verweij, PE, Kema, GH, Zwaan, B, Melchers, WJ, Triazole fungicides and the selection of resistance to medical triazoles in the opportunistic mould Aspergillus fumigatus. Pest Manag Sci 69 (2013), 165–170.
22. 22 Adams, TH, Wieser, JK, Yu, JH, Asexual sporulation in Aspergillus nidulans. Microbiol Mol Biol Rev 62 (1998), 35–54.
23. 23 Zhang, J, Debets, AJ, Verweij, PE, Melchers, WJ, Zwaan, BJ, Schoustra, SE, Asexual sporulation facilitates adaptation: The emergence of azole resistance in Aspergillus fumigatus. Evolution 69 (2015), 2573–2586.
24. 24 Casselton, L, Zolan, M, The art and design of genetic screens: filamentous fungi. Nat Rev Genet 3 (2002), 683–697.
25. 25 O'Gorman, CM, Fuller, H, Dyer, PS, Discovery of a sexual cycle in the opportunistic fungal pathogen Aspergillus fumigatus. Nature 457 (2009), 471–475.
26. 26 Sugui, JA, Losada, L, Wang, W, et al. Identification and characterization of an Aspergillus fumigatus “supermater” pair. mBio, 2, 2011, e00234 e00211.
27. 27 Bhabhra, R, Miley, MD, Mylonakis, E, et al. Disruption of the Aspergillus fumigatus gene encoding nucleolar protein CgrA impairs thermotolerant growth and reduces virulence. Infect Immun 72 (2004), 4731–4740.
28. 28 Dyer, PS, O'Gorman, CM, Sexual development and cryptic sexuality in fungi: insights from Aspergillus species. FEMMS Microbiol Rev 36 (2012), 165–192.
29. 29 Pontecorvo, G, The parasexual cycle in fungi. Annu Rev Microbiol 10 (1956), 393–400.
30. 30 Strømnæs, Ø, Garber, ED, Heterocaryosis and the parasexual cycle in Aspergillus fumigatus. Genetics 48 (1963), 653–662.
31. 31 Dalhoff, AA, Levy, SB, Does use of the polyene natamycin as a food preservative jeopardise the clinical efficacy of amphotericin B? A word of concern. Int J Antimicrob Agents 45 (2015), 564–567.
32. 32 Meletiadis, J, Antachopoulos, C, Stergiopoulou, T, Pournaras, S, Roilides, E, Walsh, TJ, Differential fungicidal activities of amphotericin B and voriconazole against Aspergillus species determined by microbroth methodology. Antimicrob Agents Chemother 51 (2007), 3329–3337.
33. 33 Elefanti, A, Mouton, JW, Krompa, K, et al. Inhibitory and fungicidal effects of antifungal drugs against Aspergillus species in the presence of serum. Antimicrob Agents Chemother 57 (2013), 1625–1631.
34. 34 Tashiro, M, Izumikawa, K, Hirano, K, et al. Correlation between triazole treatment history and susceptibility in clinically isolated Aspergillus fumigatus. Antimicrob Agents Chemother 56 (2012), 4870–4875.
35. 35 Howard, SJ, Arendrup, MC, Acquired antifungal drug resistance in Aspergillus fumigatus: epidemiology and detection. Med Mycol 49:suppl 1 (2011), S90–S95.
36. 36 Snelders, E, Melchers, WJ, Verweij, PE, Azole resistance in Aspergillus fumigatus: a new challenge in the management of invasive aspergillosis?. Future Microbiol 6 (2011), 335–347.
37. 37 Denning, DW, Park, S, Lass-Florl, C, et al. High-frequency triazole resistance found in nonculturable Aspergillus fumigatus from lungs of patients with chronic fungal disease. Clin Infect Dis 52 (2011), 1123–1129.
38. 38 Chryssanthou, E, In vitro susceptibility of respiratory isolates of Aspergillus species to itraconazole and amphotericin B. Acquired resistance to itraconazole. Scand J Infect Dis 29 (1997), 509–512.
39. 39 Dannaoui, E, Borel, E, Monier, MF, Piens, MA, Picot, S, Persat, F, Acquired itraconazole resistance in Aspergillus fumigatus. J Antimicrob Chemother 47 (2001), 333–340.
40. 40 Chen, J, Li, H, Li, R, Bu, D, Wan, Z, Mutations in the cyp51A gene and susceptibility to itraconazole in Aspergillus fumigatus serially isolated from a patient with lung aspergilloma. J Antimicrob Chemother 55 (2005), 31–37.
41. 41 Bellete, B, Raberin, H, Morel, J, Flori, P, Hafid, J, Manhsung, RT, Acquired resistance to voriconazole and itraconazole in a patient with pulmonary aspergilloma. Med Mycol 48 (2010), 197–200.
42. 42 Howard, SJ, Pasqualotto, AC, Anderson, MJ, et al. Major variations in Aspergillus fumigatus arising within aspergillomas in chronic pulmonary aspergillosis. Mycoses 56 (2013), 434–441.
43. 43 Campbell, MJ, Clayton, YM, Bronchopulmonary aspergillosis. A correlation of the clinical and laboratory findings in 272 patients investigated for bronchopulmonary aspergillosis. Am Rev Respir Dis 89 (1964), 186–196.
44. 44 Albarrag, AM, Anderson, MJ, Howard, SJ, et al. Interrogation of related clinical pan-azole-resistant Aspergillus fumigatus strains: G138C, Y431C, and G434C single nucleotide polymorphisms in cyp51A, upregulation of cyp51A, and integration and activation of transposon Atf1 in the cyp51A promoter. Antimicrob Agents Chemother 55 (2011), 5113–5121.
45. 45 Shalhoub, S, Luong, ML, Howard, SJ, et al. Rate of cyp51A mutation in Aspergillus fumigatus among lung transplant recipients with targeted prophylaxis. J Antimicrob Chemother 70 (2015), 1064–1067.
46. 46 van der Linden, JW, Snelders, E, Kampinga, GA, et al. Clinical implications of azole resistance in Aspergillus fumigatus, The Netherlands, 2007–2009. Emerg Infect Dis 17 (2011), 1846–1854.
47. 47 van der Linden, JW, Camps, SM, Kampinga, GA, et al. Aspergillosis due to voriconazole highly resistant Aspergillus fumigatus and recovery of genetically related resistant isolates from domiciles. Clin Infect Dis 57 (2013), 513–520.
48. 48 Mortensen, KL, Jensen, RH, Johansen, HK, et al. Aspergillus species and other molds in respiratory samples from patients with cystic fibrosis: a laboratory-based study with focus on Aspergillus fumigatus azole resistance. J Clin Microbiol 49 (2011), 2243–2251.
49. 49 Fischer, J, van Koningsbruggen-Rietschel, S, Rietschel, E, et al. Prevalence and molecular characterization of azole resistance in Aspergillus spp. isolates from German cystic fibrosis patients. J Antimicrob Chemother 69 (2014), 1533–1536.
50. 50 Morio, F, Aubin, GG, Danner-Boucher, I, et al. High prevalence of triazole resistance in Aspergillus fumigatus, especially mediated by TR/L98H, in a French cohort of patients with cystic fibrosis. J Antimicrob Chemother 67 (2012), 1870–1873.
51. 51 Burgel, PR, Baixench, MT, Amsellem, M, et al. High prevalence of azole-resistant Aspergillus fumigatus in adults with cystic fibrosis exposed to itraconazole. Antimicrob Agents Chemother 56 (2012), 869–874.
52. 52 Shopova, I, Bruns, S, Thywissen, A, Kniemeyer, O, Brakhage, AA, Hillmann, F, Extrinsic extracellular DNA leads to biofilm formation and colocalizes with matrix polysaccharides in the human pathogenic fungus Aspergillus fumigatus. Front Microbiol, 4, 2013, 141.
53. 53 de Valk, HA, Klaassen, CHW, Yntema, JB, et al. Molecular typing and colonization patterns of Aspergillus fumigatus in patients with cystic fibrosis. J Cyst Fibros 8 (2009), 110–114.
54. 54 de Valk, HA, Meis, JF, de Pauw, BE, Donnelly, PJ, Klaassen, CH, Comparison of two highly discriminatory molecular fingerprinting assays for analysis of multiple Aspergillus fumigatus isolates from patients with invasive aspergillosis. J Clin Microbiol 45 (2007), 1415–1419.
55. 55 Zelante, T, Iannitti, RG, De Luca, A, et al. Sensing of mammalian IL-17A regulates fungal adaptation and virulence. Nat Commun, 3, 2012, 683.
56. 56 Chauhan, N, Latge, JP, Calderone, R, Signaling and oxidant adaptation in Candida albicans and Aspergillus fumigatus. Nat Rev Microbiol 4 (2006), 435–444.
57. 57 Delsing, CE, Becker, KL, Simon, A, et al. Th17 cytokine deficiency in patients with Aspergillus skull base osteomyelitis. BMC Infect Dis, 15, 2015, 140.
58. 58 Taylor, PR, Roy, S, Leal, SM Jr, et al. Activation of neutrophils by autocrine IL-17A-IL-17RC interactions during fungal infection is regulated by IL-6, IL-23, RORγt and dectin-2. Nat Immunol 15 (2014), 143–151.
59. 59 Mowat, E, Lang, S, Williams, C, McCulloch, E, Jones, B, Ramage, G, Phase-dependent antifungal activity against Aspergillus fumigatus developing multicellular filamentous biofilms. J Antimicrob Chemother 62 (2008), 1281–1284.
60. 60 Sun, WK, Lu, X, Li, X, et al. Dectin-1 is inducible and plays a crucial role in Aspergillus-induced innate immune responses in human bronchial epithelial cells. Eur J Clin Microbiol Infect Dis 31 (2012), 2755–2764.
61. 61 Anderson, JB, Evolution of antifungal drug resistance: mechanisms and pathogen fitness. Nat Rev Microbiol 3 (2005), 547–556.
62. 62 Schoustra, SE, Debets, AJM, Slakhorst, M, Hoekstra, RF, Reducing the cost of resistance; experimental evolution in the filamentous fungus Aspergillus nidulans. J Evol Biol 19 (2006), 1115–1127.
63. 63 Chowdhary, A, Kathuria, S, Xu, J, Meis, JF, Emergence of azole-resistant Aspergillus fumigatus strains due to agricultural azole use creates an increasing threat to human health. PLoS Pathog, 9, 2013, e1003633.
64. 64 Mavridou, E, Meletiadis, J, Jancura, P, et al. Composite survival index to compare virulence changes in azole-resistant Aspergillus fumigatus clinical isolates. PLoS One, 8, 2013, e72280.
65. 65 Denning, DW, Cadranel, J, Beigelman-Aubry, C, et al. Chronic pulmonary aspergillosis—Rationale and clinical guidelines for diagnosis and management. Eur Respir J 47 (2016), 45–68.
66. 66 van Ingen, J, van der Lee, HA, Rijs, AJ, Snelders, E, Melchers, WJ, Verweij, PE, High-level pan-azole-resistant aspergillosis. J Clin Microbiol 53 (2015), 2343–2345.
67. 67 Verweij, PE, Ananda-Rajah, M, Andes, D, et al. International expert opinion on the management of infection caused by azole-resistant Aspergillus fumigatus. Drug Resist Updat 21–22 (2015), 30–40.
68. 68 Sharma, C, Hagen, F, Moroti, R, Meis, JF, Chowdhary, A, Triazole-resistant Aspergillus fumigatus harbouring G54 mutation: Is it de novo or environmentally acquired?. J Glob Antimicrob Resist 3 (2015), 69–73.
69. 69 Bader, O, Tünnermann, J, Dudakova, A, Tangwattanachuleeporn, M, Weig, M, Groß, U, Environmental isolates of azole-resistant Aspergillus fumigatus in Germany. Antimicrob Agents Chemother 59 (2015), 4356–4359.
70. 70 Shao, C, Qu, J, He, L, et al. Transient overexpression of gamma interferon promotes Aspergillus clearance in invasive pulmonary aspergillosis. Clin Exp Immunol 142 (2005), 233–241.
71. 71 Hagiwara, D, Takahashi, H, Watanabe, A, et al. Whole-genome comparison of Aspergillus fumigatus strains serially isolated from patients with aspergillosis. J Clin Microbiol 52 (2014), 4202–4209.
72. 72 Takahashi-Nakaguchi, A, Muraosa, Y, Hagiwara, D, et al. Genome sequence comparison of Aspergillus fumigatus strains isolated from patients with pulmonary aspergilloma and chronic necrotizing pulmonary aspergillosis. Med Mycol 53 (2015), 353–360.
73. 73 Camps, SMT, Dutilh, BE, Arendrup, MC, et al. Discovery of a hapE mutation that causes azole resistance in Aspergillus fumigatus through whole genome sequencing and sexual crossing. PLos One, 11, 2012, e50034.
74. 74 Losada, L, Sugui, JA, Eckhaus, MA, et al. Genetic analysis using an isogenic mating pair of Aspergillus fumigatus identifies azole resistance genes and lack of MAT locus's role in virulence. PLoS Pathog, 11, 2015, e1004834.